Preclinical
EC1456 – Cancer
Description:
EC1456 targets a chemotherapy drug to folate receptors over expressed on cancer cells. EC1456 targets a “super-potent” chemotherapy drug called tubulysin using our second-generation guidance system.
Development Stage:
EC1456 is currently in preclinical development.
EC1719 – Cancer
Description:
EC1719 targets a chemotherapy drug to PSMA receptors expressed on prostate cancer cells. EC1719 is constructed with a proprietary, high affinity targeting ligand that binds to PSMA together with a potent chemotherapy drug that inhibits microtubule activity.
Development Stage:
EC1719 is currently in preclinical development.
EC1669 – Anti-inflammatory
Description:
EC1669 targets a highly potent anti-folate drug to activated macrophages overexpressing folate receptors.
Development Stage:
EC1669 is currently in preclinical development.
EC0371 – Polycystic Kidney Disease (PKD)
Description:
EC0371 is a folate-targeted, water soluble form of rapamycin that selectively inhibits mTOR activity in polycystic kidneys to reduce abnormal growth.
Development Stage:
EC0371 is currently in preclinical development.
